Intermittent Fasting Versus Daily Caloric Restriction for Weight Loss
Comparison of Weight Loss Induced by Intermittent Fasting Versus Daily Caloric Restriction in Individuals With Obesity: A 1-Year Randomized Trial
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Colorado
-
Aurora, Colorado, United States, 80045
- Kristen Bing
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Female or Male
- Age 18-60 years
- Body Mass Index 27-46 kg/m2
- Sedentary: defined as <150 minutes per week of voluntary exercise at moderate intensity or greater and < 60 min per day of total habitual physical activity (i.e. work related, transportation related) at moderate intensity or greater, over the past 3 months.
- No self-report of acute or chronic disease (cardiovascular disease (CVD), diabetes, gastrointestinal disorders and orthopedic problems in particular)
- No plans to relocate within the next 12 months
- No plans for extended travel (> 2 weeks) within the next 12 months
- No nicotine use
- Live or work within 30 minutes of the Anschutz Health and Wellness Center (AHWC) (exceptions may be made at the discretion of the Study PI on a case by case basis for highly motivated subjects).
- Capable and willing to give informed consent, understand exclusion criteria, and accept the randomized group assignment.
- Have a primary care physician (or are willing to establish care with a primary care physician prior to study enrollment) to address medical issues which may arise during screening or study procedures/interventions.
For Females
- Not currently pregnant or lactating
- Not pregnant within the past 6 months
- Not planning to become pregnant in the next 12 months;
- Sexually active women of childbearing potential may be enrolled if they have had a tubal ligation or use a reliable means of contraception
Exclusion Criteria
- Diastolic blood pressure > 100 mm of Mercury (HG) or systolic blood pressure > 160 mm HG.
- Resting heart rate >100
- Diabetes (fasting glucose ≥126 mg/dL or Glycated Hemoglobin (A1C) ≥6.5%)
- Undiagnosed hypo- or hyper-thyroidism (TSH outside of the normal range) or history of uncontrolled thyroid disorder. History of thyroid disease or current thyroid disease treated with a stable medication regimen for at least 6 months is acceptable.
- Hematocrit, white blood cell count or platelets significantly outside the normal reference range.
- Triglycerides > 400 mg/dL
- LDL cholesterol > 200 mg/dL
- Abnormal resting electrocardiogram (ECG): serious arrhythmias, including multifocal Premature Ventricular Contractions (PVC's), frequent PVC's (defined as 10 or more per min), ventricular tachycardia (defined as runs of 3 or more successive PVC's), or sustained atrial tachyarrhythmia; 2nd or 3rd degree A-V block, QTc (Q-T Corrected) interval > 480 msec or other significant conduction defects.
- Presence or history of any metabolic or chronic health problems which would affect appetite, food intake, energy metabolism, or ability to optimally participate in the exercise component including: CVD, peripheral vascular disease, cerebrovascular disease, significant cardiac arrhythmias or cardiac valve disease, diabetes, uncontrolled hyper- or hypothyroidism, uncontrolled hypertension, cancer (within the last 5 years, except skin cancer or other cancers considered cured with excellent prognosis), HIV infection, significant gastrointestinal disorders (described below), significant pulmonary disorders (described below), significant renal, musculoskeletal, neurologic, hematologic, or psychiatric disease.
- Significant gastrointestinal disorders including: chronic malabsorptive conditions, peptic ulcer disease, Crohn's disease, Ulcerative Colitis, chronic diarrhea, or active gallbladder disease.
- Significant pulmonary disorders including: chronic obstructive pulmonary disease (COPD), interstitial lung disease, cystic fibrosis, or uncontrolled asthma.
- Symptoms suggestive of CVD: chest pain, shortness of breath at rest or with mild exertion, syncope.
- Regular use of prescription or over-the-counter medications known to significantly impact appetite, weight, or energy metabolism
- Regular use of systemic steroids (other than Oral Contraceptive Pills).
- Regular use of obesity pharmacotherapeutic agents within the last 6 months.
- Previous obesity treatment with surgery or weight loss device, except: (1) liposuction and/or abdominoplasty if performed > 1 year before screening, (2) lap banding if the band has been removed > 1 year before screening, (3) intragastric balloon if the balloon has been removed > 1 year before screening (4) duodenal-jejunal bypass sleeve, if the sleeve has been removed > 1 year before screening or 5) AspireAssist or other endoscopically placed weight loss device if the device has been removed > 1 year before screening.
- Current alcohol or substance abuse
- Nicotine use (past 6 months)
- History of clinically diagnosed eating disorders including anorexia nervosa, bulimia, binge eating disorder.
- Current severe depression or history of severe depression within the previous year, based on Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR) criteria for Major Depressive Episode.
- History of other significant psychiatric illness (e.g. psychosis, schizophrenia, mania, bipolar disorder) which in the opinion of the Study MD would interfere with ability to adhere to dietary or exercise interventions.
- Currently participating in or planning to participate in any formal weight loss or physical activity programs or clinical trials.
- Weight loss >5kg in past 3 months for any reason except post-partum weight loss, weight gain >5kg in past 3 months requires assessment by PI to determine reason for weight gain and if it is appropriate for the subject to participate in the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: Daily Caloric Restriction (DCR)
Participants in this group will focus on daily calorie restriction as their dietary weight loss strategy.
|
Participants in this group will be given a calorie goal designed to produce a 34.3% energy deficit from estimated baseline weight maintenance energy requirements.
Participants in this group will also receive a 12 month comprehensive group-based behavioral weight loss program and will be instructed in specific strategies to support DCR. Randomized groups will meet separately.
Participants in this group will also be asked to increase moderate intensity physical activity to a target of 300 minutes per week.
|
|
Experimental: Intermittent Fasting (IMF)
Participants in this group will focus on modified intermittent fasting as their dietary weight loss strategy.
|
Participants in this group will be instructed to limit energy intake to 20% of estimated baseline energy requirements on three non-consecutive days per week, and to eat ad libitum the other 4 days per week.
Participants in this group will also receive a 12 month comprehensive group based behavioral weight loss program and will be instructed in specific strategies to support IMF. Randomized groups will meet separately.
Participants in this group will also be asked to increase moderate intensity physical activity to a target of 300 minutes per week.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in Body Weight
Time Frame: Baseline and weeks 4, 13, 26, 39, 52.
|
Body weight will be measured via clinic scale.
|
Baseline and weeks 4, 13, 26, 39, 52.
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in Body Weight
Time Frame: Week 78.
|
Body weight will be measured via clinic scale.
The 78 month time point was added via a protocol amendment after study start.
This is not a primary outcome, but rather a 6-month post-primary outcome follow-up weight.
|
Week 78.
|
|
Changes in Body Composition
Time Frame: Baseline and weeks 26, 52, and 78.
|
Body composition will be assessed with dual-energy x-ray absorptiometry (DXA).The 78 week time point was added via a protocol amendment after study start.
This is not a primary outcome, but rather a 6-month post-primary outcome follow-up measure.
|
Baseline and weeks 26, 52, and 78.
|
|
Changes in Blood Pressure
Time Frame: Baseline and weeks 13, 26, 52, and 78.
|
Blood pressure will be measured with a sphygomanometer.
The 78 week time point was added via a protocol amendment after study start.
This is not a primary outcome, but rather a 6-month post-primary outcome follow-up measure.
|
Baseline and weeks 13, 26, 52, and 78.
|
|
Changes in Fasting Lipids
Time Frame: Baseline and weeks 26, 52, and 78.
|
12 hour fasting blood sample for measurement of lipid profile.The 78 week time point was added via a protocol amendment after study start.
This is not a primary outcome, but rather a 6-month post-primary outcome follow-up measure.
|
Baseline and weeks 26, 52, and 78.
|
|
Changes in Insulin Sensitivity
Time Frame: Baseline and weeks 26, 52, and 78.
|
12 hour fasting blood sample for measurement of insulin and glucose.
Insulin sensitivity (homeostasis model assessment of insulin resistance [HOMA-IR]) will be calculated as ([insulin] x [fasting glucose x 0.055]/22.5).
The 78 week time point was added via a protocol amendment after study start.
This is not a primary outcome, but rather a 6-month post-primary outcome follow-up measure.
|
Baseline and weeks 26, 52, and 78.
|
|
Changes in Objectively Measured Energy Intake (EI)
Time Frame: Baseline, weeks 26, 52, and 78.
|
EI will be measured using the doubly-labeled water (DLW) intake-balance method.
The 78 week time point was added via a protocol amendment after study start.
This is not a primary outcome, but rather a 6-month post-primary outcome follow-up measure.
|
Baseline, weeks 26, 52, and 78.
|
|
Changes in Self-Reported Energy Intake (EI)
Time Frame: Baseline and weeks 13, 26, 52, and 78.
|
Dietary energy intake (kcals/day) will be measured with diet diaries.
The 78 week time point was added via a protocol amendment after study start.
This is not a primary outcome, but rather a 6-month post-primary outcome follow-up measure.
|
Baseline and weeks 13, 26, 52, and 78.
|
|
Changes in Self-reported Diet Composition
Time Frame: Baseline and weeks 13, 26, 52, and 78.
|
Dietary macronutrient intake will be measured with diet diaries.
The 78 week time point was added via a protocol amendment after study start.
This is not a primary outcome, but rather a 6-month post-primary outcome follow-up measure.
|
Baseline and weeks 13, 26, 52, and 78.
|
|
Changes in Self-Reported Dietary Adherence
Time Frame: Weeks 4, 8, 13, 18, 22, 26, 30, 34, 39, 44, 48, 52
|
Adherence to prescribed diet will be assessed with a monthly questionnaire.
|
Weeks 4, 8, 13, 18, 22, 26, 30, 34, 39, 44, 48, 52
|
|
Changes in Resting Energy Expenditure (REE)
Time Frame: Baseline and weeks 26, 52, and 78.
|
REE will be measured using indirect calorimetry.
The 78 week time point was added via a protocol amendment after study start.
This is not a primary outcome, but rather a 6-month post-primary outcome follow-up measure.
|
Baseline and weeks 26, 52, and 78.
|
|
Changes in Total Daily Energy Expenditure (TDEE)
Time Frame: Baseline and weeks 26, 52, and 78.
|
TDEE will be measured using the doubly-labeled water (DLW) method.
The 78 week time point was added via a protocol amendment after study start.
This is not a primary outcome, but rather a 6-month post-primary outcome follow-up measure.
|
Baseline and weeks 26, 52, and 78.
|
|
Changes in Physical Activity
Time Frame: Baseline and weeks 13, 26, 52, and 78.
|
Physical activity will be measured with activity monitors.
The 78 week time point was added via a protocol amendment after study start.
This is not a primary outcome, but rather a 6-month post-primary outcome follow-up measure.
|
Baseline and weeks 13, 26, 52, and 78.
|
|
Changes in Sedentary Behavior
Time Frame: Baseline and weeks 13, 26, 52, and 78.
|
Sedentary behavior will be measured with activity monitors.
The 78 week time point was added via a protocol amendment after study start.
This is not a primary outcome, but rather a 6-month post-primary outcome follow-up measure.
|
Baseline and weeks 13, 26, 52, and 78.
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Victoria Catenacci, MD, University of Colorado Anschutz Health and Wellness Center
Publications and helpful links
General Publications
- Breit MJ, Pan Z, Ostendorf DM, Dahle JH, Catenacci VA, Creasy SA, Melanson EL. Using Time-Weighted Averages of Total Daily Energy Expenditure to Estimate Energy Intake During a Weight Loss Intervention. Obesity (Silver Spring). 2025 Nov;33(11):2093-2102. doi: 10.1002/oby.70008. Epub 2025 Aug 28.
- Catenacci VA, Ostendorf DM, Pan Z, Kaizer LK, Creasy SA, Zaman A, Caldwell AE, Dahle J, Swanson B, Breit MJ, Bing K, Wayland LT, Panter SL, Scorsone JJ, Bessesen DH, MacLean P, Melanson EL. The Effect of 4:3 Intermittent Fasting on Weight Loss at 12 Months : A Randomized Clinical Trial. Ann Intern Med. 2025 May;178(5):634-644. doi: 10.7326/ANNALS-24-01631. Epub 2025 Apr 1.
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 17-0369
- R01DK111622-01A1 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Obesity
-
NCT06671119RecruitingObesity Prevention | Obesity Recidivism | Obesity and Overweight | Obesity and Obesity-related Medical Conditions
-
NCT05938335Not yet recruiting
-
NCT02645422Enrolling by invitation
-
NCT04780828CompletedObesity, Morbid | Obesity, Adolescent | Obesity, Abdominal | Weight, Body | Obesity, Visceral
-
NCT03843424CompletedOvernutrition | Nutrition Disorders | Overweight | Body Weight | Pediatric Obesity | Body Weight Changes | Childhood Obesity | Weight Gain | Adolescent Obesity | Obesity, Childhood
-
NCT03219658Completed
-
NCT03899311Completed
-
NCT03203161Not yet recruitingMorbid Obesity | Adolescent Obesity | Bariatric Surgery
-
NCT06734312RecruitingObesity Prevention | Obesity Recidivism | Obesity and Overweight | GLP-1 | Obesity and Obesity-related Medical Conditions | Ablation Techniques
-
NCT04698135CompletedMorbid Obesity | Metabolically Healthy Obesity
Clinical Trials on Daily Caloric Restriction (DCR)
-
NCT04907799Active, not recruitingOverweight and Obesity | Autosomal Dominant Polycystic Kidney
-
NCT00383253Completed
-
NCT03365531TerminatedObesity | Diabetes Mellitus, Type 2 | NAFLD
-
NCT06496542Active, not recruitingAutosomal Dominant Polycystic Kidney
-
NCT04042415Active, not recruitingMultiple Sclerosis, Relapsing-Remitting | Caloric Restriction
-
NCT02450097CompletedObesity | Diabetes Type 2
-
NCT02533479Completed
-
NCT01329822CompletedOverweight | Type 2 Diabetes